Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tonix Pharmaceuticals Holding (TNXP) EBIT Margin: 2023-2025

Historic EBIT Margin for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to -1,005.08%.

  • Tonix Pharmaceuticals Holding's EBIT Margin fell 45391.00% to -1,005.08% in Q3 2025 from the same period last year, while for Sep 2025 it was -969.97%, marking a year-over-year increase of 28369.00%. This contributed to the annual value of -1,354.28% for FY2024, which is 16966.00% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its EBIT Margin stood at -1,005.08% for Q3 2025, which was up 29.03% from -1,416.22% recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's EBIT Margin's 5-year high stood at -551.17% during Q3 2024, with a 5-year trough of -3,501.63% in Q2 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median EBIT Margin value was -860.23% (recorded in 2024), while the average stood at -1,143.86%.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's EBIT Margin showed a top increase of 208,541bps in 2025 and a maximum decrease of 45,391bps in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's EBIT Margin (Quarterly) stood at -723.18% in 2023, then tumbled by 14,746bps to -870.64% in 2024, then plummeted by 45,391bps to -1,005.08% in 2025.
  • Its EBIT Margin was -1,005.08% in Q3 2025, compared to -1,416.22% in Q2 2025 and -660.93% in Q1 2025.